Off-Label Promotion Settlement Includes Optional Preclearance Process
This article was originally published in The Gray Sheet
Executive Summary
Amarin may submit up to two proposed communications annually to FDA about unapproved use of its triglyceride-lowering drug Vascepa, and the agency must respond with any concerns within 60 calendar days.